CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Interrelationship between Reduction in Weight and Adiposity Indices and Improvement in Cardiovascular (CV) Death and Heart Failure (HF) Outcomes with Empagliflozin in Patients with Type 2 Diabetes (T2D) in EMPA-REG OUTCOME®
DOI 10.1055/s-0038-1641827
Bibliografische Angaben
Nachweis in CareLit
Autor:innenIJ Neeland, DK McGuire, U Hehnke, HJ Woerle, D Fitchett, OE Johansen
ZeitschriftDiabetologie und Stoffwechsel
AusgabeS 01 S 01/2018
Jahrgang / SeitenJg. 13
Kernaussage aus der Literatur
Abstract-Vorschau
Interrelationship between Reduction in Weight and Adiposity Indices and Improvement in Cardiovascular (CV) Death and Heart Failure (HF) Outcomes with Empagliflozin in Patients with Type 2 Diabetes (T2D) in EMPA-REG OUTCOME®
Zitieren
Zitierempfehlung
IJ Neeland, DK McGuire, U Hehnke, HJ Woerle, D Fitchett, OE Johansen (2018) Interrelationship between Reduction in Weight and Adiposity Indices and Improvement in Cardiovascular (CV) Death and Heart Failure (HF) Outcomes with Empagliflozin in Patients with Type 2 Diabetes (T2D) in EMPA-REG OUTCOME®. Diabetologie und Stoffwechsel, 13 (S 01 S 01). https://doi.org/10.1055/s-0038-1641827
Mit CareLit weiterarbeiten